Anti‐FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer

There is no clinically available biomarker for efficiently indicating the overall survival or therapy response of gastric cancer (GC). The autoantibodies (Abs) in the sera of anti‐far‐upstream element‐binding protein‐interacting repressor‐lacking exon2 (FIRΔexon2), anti‐sorting nexin 15, and anti‐sp...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Sci
Huvudupphovsmän: Kobayashi, Sohei, Hiwasa, Takaki, Ishige, Takayuki, Kano, Masayuki, Hoshino, Tyuji, Rahmutulla, Bahityar, Seimiya, Masanori, Shimada, Hideaki, Nomura, Fumio, Matsubara, Hisahiro, Matsushita, Kazuyuki
Materialtyp: Artigo
Språk:Inglês
Publicerad: John Wiley and Sons Inc. 2021
Ämnen:
Original Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7894018/
https://ncbi.nlm.nih.gov/pubmed/33306856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14767
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk